Bangladesh Endocrine Society (BES) Position Statement for Management of Diabetes and Other Endocrine Diseases in Patients with COVID-19

References

• Chen Y , Gong X , Wang L , Guo J . Effects of hypertension, diabetes and coronary heart disease on COVID-19 diseases severity: a systematic review and meta-analysis. medRxiv . 2020.
   Google Scholar
• Bornstein SR , Rubino F , Khunti K , et al. Practical recommendations for the management of diabetes in patients with COVID-19. Lancet Diabetes Endocrinol . 2020;8(6):546–550. doi:10.1016/S2213-8587(20)30152-2 32334646
   PubMed Web of Science ®Google Scholar
• Latif ZA , Ashrafuzzaman SM , Amin MF , Gadekar A , Sobhan MJ , Haider T . A cross-sectional Study to evaluate diabetes management, control and complications in patients with type 2 diabetes in Bangladesh. BIRDEM Med J . 2017;7(1):17–27. doi:10.3329/birdem.v7i1.31268
   Google Scholar
• Remuzzi A , Remuzzi G . COVID-19 and Italy: what next? Lancet . 2020;395(10231):1225–1228. doi:10.1016/S0140-6736(20)30627-9 32178769
   PubMed Web of Science ®Google Scholar
• Barrera FJ , Shekhar S , Wurth R , et al. Prevalence of diabetes and hypertension and their associated risks for poor outcomes in Covid-19 patients. J Endocr Soc . 2020;4(9):bvaa102. doi:10.1210/jendso/bvaa102 32885126
   PubMed Web of Science ®Google Scholar
• Roncon L , Zuin M , Rigatelli G , Zuliani G . Diabetic patients with COVID-19 infection are at higher risk of ICU admission and poor short-term outcome. J Clin Virol . 2020;127:104354. doi:10.1016/j.jcv.2020.104354 32305882
   PubMed Web of Science ®Google Scholar
• Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19). World Health Organization; 2020. Available from: https://www.who.int/publications/i/item/report-of-the-who-china-joint-mission-on-coronavirus-disease-2019-(covid-19). Accessed 6 21 2020.
   Google Scholar
• The Novel Coronavirus Pneumonia Emergency Response Epidemiology Team. The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19)-China, 2020. China CDC Weekly . 2020;2(8):113–122. doi:10.46234/ccdcw2020.032
   PubMedGoogle Scholar
• Zhang B , Zhou X , Qiu Y , et al. Clinical Characteristics of 82 Death Cases with COVID-19. medRxiv . 2020.
   Google Scholar
• Alshaikh A , Alsifri S , Alhozali A , et al. Saudi Scientific Diabetes Society Position Statement: management of diabetes mellitus in the pandemic of COVID-19. Int J Clin Med . 2020;11(05):199–206. doi:10.4236/ijcm.2020.115020
   Google Scholar
• Gupta R , Hussain A , Misra A . Diabetes and COVID-19: evidence, current status and unanswered research questions. Eur J Clin Nutr . 2020;74(6):864–870. doi:10.1038/s41430-020-0652-1 32404898
   PubMed Web of Science ®Google Scholar
• Guo W , Li M , Dong Y , et al. Diabetes is a risk factor for the progression and prognosis of COVID-19. Diabetes Metab Res Rev . 2020;e3319.32233013
   PubMed Web of Science ®Google Scholar
• Hoffmann M , Kleine-Weber H , Schroeder S , et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell . 2020;181(2):271–280. doi:10.1016/j.cell.2020.02.052 32142651
   PubMed Web of Science ®Google Scholar
• Bindom SM , Lazartigues E . The sweeter side of ACE2: physiological evidence for a role in diabetes. Mol Cell Endocrinol . 2009;302(2):193–202. doi:10.1016/j.mce.2008.09.020 18948167
   PubMed Web of Science ®Google Scholar
• Roca-Ho H , Riera M , Palau V , Pascual J , Soler MJ . Characterization of ACE and ACE2 expression within different organs of the NOD mouse. Int J Mol Sci . 2017;18(3):e563. doi:10.3390/ijms18030563 28273875
   PubMed Web of Science ®Google Scholar
• Yang JK , Lin SS , Ji XJ , Guo LM . Binding of SARS coronavirus to its receptor damages islets and causes acute diabetes. Acta Diabetol . 2010;47(3):193–199. doi:10.1007/s00592-009-0109-4 19333547
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. 6. Glycemic targets: standards of medical care in diabetes-2020. Diabetes Care . 2020;43(Suppl. 1):S66–S76. doi:10.2337/dc20-S006 31862749
   PubMed Web of Science ®Google Scholar
• Cemiyeti TD . Expert recommendation on glucose management strategies of diabetes combine with COVID-19. J Clin Intern Med . 2020;37(3):215–219.
   Google Scholar
• Banerjee M , Chakraborty S , Pal R . Diabetes self-management amid COVID-19 pandemic. Diabetes Metab Syndr . 2020;14(4):351–354. doi:10.1016/j.dsx.2020.04.013 32311652
   PubMed Web of Science ®Google Scholar
• Basu A , Slama MQ , Nicholson WT , et al. Continuous glucose monitor interference with commonly prescribed medications: a pilot study. J Diabetes Sci Technol . 2017;11(5):936e41. doi:10.1177/1932296817697329 28332406
   PubMedGoogle Scholar
• Rao PV , Makkar BM , Kumar A , et al. RSSDI consensus on self-monitoring of blood glucose in types 1 and 2 diabetes mellitus in India. Int J Diabetes Dev Ctries . 2018;38(3):260–279. doi:10.1007/s13410-018-0677-3
   Web of Science ®Google Scholar
• Schuster KM , Barre K , Inzucchi SE , et al. Continuous glucose monitoring in the surgical intensive care unit: concordance with capillary glucose. J Trauma Acute Care Surg . 2014;76(3):798e803. doi:10.1097/TA.0000000000000127 24553551
   PubMed Web of Science ®Google Scholar
• Wang A , Zhao W , Xu Z , Gu J . Timely blood glucose management for the outbreak of 2019 novel coronavirus disease (COVID-19) is urgently needed. Diabetes Res Clin Pract . 2020;162:108118. doi:10.1016/j.diabres.2020.108118 32179126
   PubMed Web of Science ®Google Scholar
• Sick day rules: how to manage Type 2 diabetes if you become unwell with coronavirus and what to do with your medication. London: NHS; 2020. Available from: https://www.england.nhs.uk/london/wp-content/uploads/sites/8/2020/04/3.-Covid-19-Type-2-Sick-Day-Rules-Crib-Sheet-06042020.pdf. Accessed 6 22, 2020.
   Google Scholar
• Matthews R Medscape diabetes and endocrinology, glucose control key with COVID-19 in diabetes; 2020. Available from: https://www.medscape.com/viewarticle/927044#vp_2. Accessed 3 8, 2020.
   Google Scholar
• Barazzoni R , Bischoff SC , Krznaric Z , Pirlich M , Singer P . ESPEN expert statements and practical guidance for nutritional management of individuals with sars-cov-2 infection. Clin Nutr . 2020;39:1631–1638. doi:10.1016/j.clnu.2020.03.022 32305181
   PubMed Web of Science ®Google Scholar
• Vitamin D deficiency in Ireland– implications for COVID-19: results from the Irish Longitudinal Study on Ageing (TILDA). Dublin: Irish Longitudinal Study on Ageing (TILDA); 2020. Available from: https://tilda.tcd.ie/publications/reports/pdf/Report_Covid19VitaminD.pdf. Accessed 2 07, 2021.
   Google Scholar
• Ghaffari H , Tavakoli A , Moradi A , et al. Inhibition of H1N1 influenza virus infection by zinc oxide nanoparticles: another emerging application of nanomedicine. J Biomed Sci . 2019;26(1):70. doi:10.1186/s12929-019-0563-4 31500628
   PubMed Web of Science ®Google Scholar
• Hemilä H . Vitamin C intake and susceptibility to pneumonia. Pediatr Infect Dis J . 1997;16(9):836–837. doi:10.1097/00006454-199709000-00003 9306475
   PubMed Web of Science ®Google Scholar
• Covid 19 and diabetes. International Diabetes Federation; 2020. Available from: https://www.idf.org/aboutdiabetes/what-is-diabetes/covid-19-and-diabetes/1-covid-19-and-diabetes. Accessed 2 07, 2021.
   Google Scholar
• Ghelichkhani P , Esmaeili M . Prone Position in Management of COVID-19 Patients; a Commentary. Arch Acad Emerg Med . 2020;8(1):e48.32309812
   PubMedGoogle Scholar
• Thomas P , Baldwin C , Bissett B , et al. Physiotherapy management for COVID-19 in the acute hospital setting: clinical practice recommendations. J Physiother . 2020;66(2):73–82. doi:10.1016/j.jphys.2020.03.011 32312646
   PubMed Web of Science ®Google Scholar
• National Guidelines on Clinical Management of COVID-19. Version 8.0. Dhaka: Directorate General of Health Services; 2020. Available from: https://dghs.gov.bd/images/docs/Guideline/COVID_Guideline_v8_2.pdf. Accessed 11 30, 2020.
   Google Scholar
• Covid-19 and Diabetes: BADAS guide for healthcare professionals. Dhaka: Diabetic Association of Bangladesh; 2020. Available from: https://drive.google.com/open?id=1F2hHB1IMjeX-KHcyHYnvHuqYzoj00Xnj. Accessed 9 30, 2020.
   Google Scholar
• Advice for healthcare professionals on coronavirus (Covid-19) and diabetes. Leicester: Leicester Diabetes Centre, Diabetes UK; 2020. Available from: https://www.diabetes.org.uk/professionals/resources/coronavirus-clinical-guidance#guidance-care-homes. Accessed 9 30, 2020.
   Google Scholar
• Mental health and psychosocial considerations during the COVID-19 outbreak.World Health Organization; 2020. Available from: https://www.who.int/publications/i/item/WHO-2019-nCoV-MentalHealth-2020.1. Accessed 23 3 2020.
   Google Scholar
• COVID-19 outbreak: guidance for people with diabetes. International Diabetes Federation; 2020. Available from: https://www.idf.org/our-network/regions-members/europe/europe-news/196-information-on-corona-virus-disease-2019-covid-19-outbreak-and-guidance-for-people-with-diabetes.html. Accessed 10 02 2020.
   Google Scholar
• Zhou G , Myers R , Li Y , et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest . 2001;108(8):1167–1174. doi:10.1172/JCI13505 11602624
   PubMed Web of Science ®Google Scholar
• Plattner F , Bibb JA . Serine and threonine phosphorylation. In: Brady ST , Siegel GJ , Albers RW , Price DL , editors. Basic Neurochemistry (Eighth Edition) . New York: Academic Press; 2012:467–492. doi:10.1016/B978-0-12-374947-5.00025-0
   Google Scholar
• Sharma S , Ray A , Sadasivam B . Metformin in COVID-19: a possible role beyond diabetes. Diabetes Res Clin Pract . 2020;164:108183. doi:10.1016/j.diabres.2020.108183 32360697
   PubMed Web of Science ®Google Scholar
• Singh AK , Khunti K . Assessment of risk, severity, mortality, glycemic control and antidiabetic agents in patients with diabetes and COVID-19: a narrative review. Diabetes Res Clin Pract . 2020;165:108266. doi:10.1016/j.diabres.2020.108266 32533989
   PubMed Web of Science ®Google Scholar
• Singh AK , Singh R , Saboo B , Misra A . Non-insulin anti-diabetic agents in patients with type 2 diabetes and COVID-19: a critical appraisal of literature. Diabetes Metab Syndr . 2020;15(1):159–167. doi:10.1016/j.dsx.2020.12.026 33352455
   PubMed Web of Science ®Google Scholar
• Gordon DE , Jang GM , Bouhaddou M , et al. A SARS-CoV-2-human protein-protein interaction map reveals drug targets and potential drug- repurposing. Nature . 2020;583(7816):459–468. doi:10.1038/s41586-020-2286-9 32353859
   PubMed Web of Science ®Google Scholar
• Iacobellis G . COVID-19 and diabetes: can DPP4 inhibition play a role? Diabetes Res Clin Pract . 2020;162:108–125. doi:10.1016/j.diabres.2020.108125
   Web of Science ®Google Scholar
• Yang W , Cai X , Han X , Ji L . DPP-4 inhibitors and risk of infections: a meta-analysis of randomized controlled trials. Diabetes Metab Res Rev . 2016;32(4):391–404. doi:10.1002/dmrr.2723 26417956
   PubMed Web of Science ®Google Scholar
• Singh A , Singh R . Dipeptidyl-peptidase-4 inhibitors in type 2 diabetes and COVID-19: from a potential repurposed agent to a useful treatment option. J Diabetol . 2020;11(3):131–136. doi:10.4103/JOD.JOD_53_20
   Google Scholar
• Pal R , Bhadada S . Should anti-diabetic medications be reconsidered amid COVID-19 pandemic? Diabetes Res Clin Pract . 2020;108146. doi:10.1016/j.diabres.2020.108146
   Google Scholar
• Ceriello A , Stoian AP , Rizzo M . COVID-19 and diabetes management: what should be considered? Diabetes Res Clin Pract . 2020;163:108151. doi:10.1016/j.diabres.2020.108151 32305399
   PubMed Web of Science ®Google Scholar
• Drucker DJ . Coronavirus infections and type 2 diabetes-shared pathways with therapeutic implications. Endocr Rev . 2020;41(3):bnaa011. doi:10.1210/endrev/bnaa011 32294179
   PubMed Web of Science ®Google Scholar
• Amin EF , Rifaai RA , Abdel-Latif RG . Empagliflozin attenuates transient cerebral ischemia/reperfusion injury in hyperglycemic rats via repressing oxidative-inflammatory-apoptotic pathway. Fundam Clin Pharmacol . 2020;34(5):548–558. PMID: 32068294. doi:10.1111/fcp.12548 32068294
   PubMed Web of Science ®Google Scholar
• Ceriello A . Thiazolidinediones as anti-inflammatory and anti-atherogenic agents. Diabetes Metab Res Rev . 2008;24(1):14–26. doi:10.1002/dmrr.790 17990280
   PubMed Web of Science ®Google Scholar
• Zhou F , Yu T , Du R , Fan G , Liu Y , Liu Z . Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet . 2020;395(10229):1054–1062. doi:10.1016/S0140-6736(20)30566-3 32171076
   PubMed Web of Science ®Google Scholar
• Singh AK , Gillies CL , Singh R , et al. Prevalence of co-morbidities and their association with mortality in patients with COVID-19: a systematic review and meta-analysis. Diabetes Obes Metab . 2020;22(10):1915–1924. doi:10.1111/dom.14124 32573903
   PubMed Web of Science ®Google Scholar
• Diabetes management during the coronavirus pandemic: be proactive and prepared. Melbourne: Royal Australian College of General Practitioners; 2020. Available from: https://www.racgp.org.au/getmedia/97a5abb4-1290-42cb-91c0-eabcaa8ca590/Diabetes-management-during-coronavirus-pandemic_1.pdf.aspx. Accessed 2 16, 2021.
   Google Scholar
• Ceriello A , Standl E , Catrinoiu D , et al.; Diabetes and Cardiovascular Disease (D&CVD) EASD Study Group. Issues of cardiovascular risk management in people with diabetes in the COVID-19 era. Diabetes Care . 2020;43(7):1427–1432. doi:10.2337/dc20-0941 32409501
   PubMed Web of Science ®Google Scholar
• Bangladesh Endocrine Society Insulin Guideline 2018. Dhaka: Bangladesh Endocrine Society; 2018. Available from: http://bes-org.net/wp-content/uploads/2019/03/Insulin%20Guideline.pdf. Accessed 6 21 2020.
   Google Scholar
• American Diabetes Association. Comprehensive Medical Evaluation and Assessment of Comorbidities: standards of Medical Care in Diabetes-2021. Diabetes Care . 2021;44(Suppl. 1):S40–S52. doi:10.2337/dc21-S004 33298415
   PubMedGoogle Scholar
• National Inpatient Diabetes Covid-19 Response Group. COncise adVice on Inpatient Diabetes (COVID: Diabetes): guidance For Managing Inpatient Hyperglycaemia. Leicester: Leicester Diabetes Centre, Diabetes UK; 2020. Available from: https://www.diabetes.org.uk/resources-s3/public/2020-04/COvID_Hyper_v4.1.pdf. Accessed 2 18, 2021.
   Google Scholar
• Rayman G , Lumb A , Kennon B , et al. London Inpatient Diabetes Network-COVID-19. Guidelines for the management of diabetes services and patients during the COVID-19 pandemic. Diabet Med . 2020;37(7):1087–1089. doi:10.1111/dme.14316 32365233
   PubMed Web of Science ®Google Scholar
• Guidance for maternal medicine in the evolving coronavirus (COVID-19) pandemic: information for healthcare professionals, Version 2.4. London: Royal college of obstetrics and gynecologists; 2020. Available from: https://www.rcog.org.uk/globalassets/documents/guidelines/2020-07-10-guidance-for-maternal-medicine.pdf. Accessed 2 20, 2021.
   Google Scholar
• Yamamoto JM , Donovan LE , Feig DS , Berger H. Urgent update– temporary alternative screening strategy for gestational diabetes screening during the COVID-19 Pandemic: a Joint Consensus Statement from the Diabetes Canada Clinical Practice Guidelines Steering Committee and the Society of Obstetricians and Gynecologists of Canada. Available from: https://www.sogc.org/common/Uploaded%20files/GDM-COVID-19%20temporary%20screening%20guidelines%20-%2020200402%20Agreed%20Final.pdf. Accessed 3 04, 2021.
   Google Scholar
• Interim U.S. Guidance for Risk Assessment and Work Restrictions for Healthcare Personnel with Potential Exposure to SARS-CoV-2. Washington: Center for Disease Control; 2021. Available from: https://www.cdc.gov/coronavirus/2019-ncov/hcp/guidance-risk-assesment-hcp.html. Accessed 3 05, 2021.
   Google Scholar
• AACE position statement: coronavirus (COVID-19) and people with adrenal insufficiency and cushing’s syndrome. USA: American Association of Clinical Endocrinologists; 2020. Available from: https://pro.aace.com/recent-news-and-updates/aace-position-statement-coronavirus-covid-19-and-people-adrenal. Accessed 3 05, 2021.
   Google Scholar
• COVID-19 and endocrine diseases, A statement from the European Society of Endocrinology. Bristol: European Society of Endocrinology; 2021. Available from: https://www.ese-hormones.org/media/2223/covid-and-endocrine-diseases-ese-statement-final_23032020.pdf. Accessed 3 06 2021.
   Google Scholar
• Rajput R , Agarwal A , Ganie MA , et al. Coronavirus disease 2019 and thyroid disease: position statement of Indian Thyroid Society. Thyroid Res Pract . 2020;17(1):4–6. doi:10.4103/trp.trp_28_20
   Google Scholar
• AACE position statement: Coronavirus (COVID-19) and people with thyroid disease [homepage on the internet]. USA: American Association of Clinical Endocrinologists; 2020. Available from: https://pro.aace.com/recent-news-and-updates/aace-position-statement-coronavirus-covid-19-and-people-thyroid-disease. Accessed 2 26, 2021.
   Google Scholar
• Foundation NO patients and providers fact sheet: injections or infusions of osteoporosis medications during the COVID-19 Pandemic cdn.nof.org2020. Arlington: National Osteoporosis Foundation; 2020. Available from: https://cdn.nof.org/wp-content/uploads/NOF-COVID-Factsheet_.pdf. Accessed 3 06, 2021.
   Google Scholar
• Liamis G , Milionis HJ , Elisaf M . Hyponatremia in patients with infectious diseases. J Infect . 2011;63(5):327–335. doi:10.1016/j.jinf.2011.07.013 21835196
   PubMed Web of Science ®Google Scholar